Antipsychotic Polypharmacy with Caplyta and Seroquel

Introduction to Antipsychotic Polypharmacy

The World Federation of Societies of Biological Psychiatry recommends antipsychotic polypharmacy (APP) only in individual cases, such as treatment-resistant schizophrenia, after adequate monotherapy trials have failed 1
Most treatment guidelines, including those from the World Federation of Societies of Biological Psychiatry, recommend antipsychotic monotherapy as the standard approach, with polypharmacy reserved for specific circumstances 1, 2

Antipsychotic polypharmacy may be appropriate for treatment-resistant schizophrenia where adequate monotherapy trials have failed 1, 2
The American Academy of Psychiatry does not have a specific guideline, but the World Federation of Societies of Biological Psychiatry suggests APP for short-term use during medication transitions, such as cross-titration periods 1
Augmentation of clozapine with another antipsychotic may be considered when clozapine monotherapy proves insufficient, as suggested by the World Federation of Societies of Biological Psychiatry 1

Before initiating APP with Caplyta and Seroquel, it is essential to confirm that adequate monotherapy trials have been attempted, including verification of medication adherence, ensuring adequate dosing, and accounting for metabolic factors 2
The World Federation of Societies of Biological Psychiatry and other guidelines emphasize the importance of documenting baseline symptoms clearly before starting APP 2

The combination of Caplyta and Seroquel may increase the risk of sedation substantially, with quetiapine being notably more sedating among atypical antipsychotics 2, 3
Monitoring for orthostatic hypotension, particularly during initiation, is crucial, as quetiapine can cause transient orthostasis 3

If APP is initiated, a structured monitoring plan should be established, including documentation of current symptomatology, scheduling follow-up within 2-4 weeks, monitoring for excessive sedation, assessing for orthostatic hypotension, tracking metabolic parameters, and evaluating treatment response 2, 3

If the patient does not improve with APP, reverting to monotherapy is recommended, with consideration of slowly and carefully switching back to monotherapy if the patient achieves stability 1, 2

Starting APP without documenting adequate monotherapy trials is a common error, and failing to verify adherence before concluding monotherapy has failed can lead to unnecessary polypharmacy 2
Inadequate monitoring after initiating the combination and continuing APP indefinitely without reassessing the need can also be problematic 2
Overlooking the long-term prevalence of APP, with up to 57.5% of patients receiving APP for extended periods, often unnecessarily, is another pitfall to avoid 1